Dual modulation of ERK1/2 and p38 MAP kinase activities induced by minocycline reverses the neurotoxic effects of the prion protein fragment 90-231

Neurotoxicity Research

Volumn 15, Issue 2, 2009, Pages 138-154

  Corsaro, Alessandro ^a   Thellung, Stefano ^a   Chiovitti, Katia ^b   Villa, Valentina ^a   Simi, Alessandro ^a   Raggi, Federica ^a   Paludi, Domenico ^c   Russo, Claudio ^d   Aceto, Antonio ^b   Florio, Tullio ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF TERAMO   (Italy)

^d UNIVERSITY OF MOLISE   (Italy)

Author keywords

Apoptosis; ERK1 2; hPrP90 231; Minocycline; p38; Prion protein

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CASPASE 3; CONGO RED; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PRION PROTEIN; PROTEIN KINASE B; THIOFLAVINE; WORTMANNIN;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DENATURATION; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; INTERNALIZATION; NERVE CELL NECROSIS; NEUROBLASTOMA CELL; NEUROMODULATION; NEUROPROTECTION; NEUROTOXICITY; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MINOCYCLINE; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEUROBLASTOMA; NEUROTOXINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PRIONS; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 70349736192     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12640-009-9015-3     Document Type: Article

References (56)

1. Aguzzi A (2006) Prion diseases of humans and farm animals: Epidemiology, genetics, and pathogenesis. J Neurochem 97:1726-1739
2. Aguzzi A, Heikenwalder M, Polymenidou M (2007) Insights into prion strains and neurotoxicity. Nat Rev Mol Cell Biol 8:552-561
3. Bate C, Salmona M, Diomede L, Williams A (2004) Squalestatin cures prion-infected neurons and protects against prion neurotoxicity. J Biol Chem 279:14983-14990
4. Bussink J, van der Kogel AJ, Kaanders JH (2008) Activation of the PI3-K/ AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 9:288-296
5. Caplazi PA, O'Rourke KI, Baszler TV (2004) Resistance to scrapie in PrP ARR/ARQ heterozygous sheep is not caused by preferential allelic use. J Clin Pathol 57:647-650
6. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6:797-801
7. Chiovitti K, Corsaro A, Thellung S, Villa V, Paludi D, D'Arrigo C, Russo C, Perico A, Ianieri A, Di Cola D, Vergara A, Aceto A, Florio T (2007) Intracellular accumulation of a mild-denatured monomer of the human PrP fragment 90-231, as possible mechanism of its neurotoxic effects. J Neurochem 103:2597-2609
8. Collinge J (1997) Human prion diseases and bovine spongiform encephalopathy (BSE). Hum Mol Genet 6:1699-1705
9. Collinge J (2001) Prion diseases of humans and animals: Their causes and molecular basis. Annu Rev Neurosci 24:519-550
10. Colucci-D'Amato L, Perrone-Capano C, di Porzio U (2003) Chronic activation of ERK and neurodegenerative diseases. Bioessays 25:1085-1095
11. Corsaro A, Thellung S, Russo C, Villa V, Arena S, D'Adamo MC, Paludi D, Rossi Principe D, Damonte G, Benatti U, Aceto A, Tagliavini F, Schettini G, Florio T (2002) Expression in E. coli and purification of recombinant fragments of wild type and mutant human prion protein. Neurochem Int 41:55-63
12. Corsaro A, Thellung S, Villa V, Principe DR, Paludi D, Arena S, Millo E, Schettini D, Damonte G, Aceto A, Schettini G, Florio T (2003) Prion protein fragment 106-126 induces a p38 MAP kinase-dependent apoptosis in SH-SY5Y neuroblastoma cells independently from the amyloid fibril formation. Ann NY Acad Sci 1010:610-622
13. Corsaro A, Paludi D, Villa V, D'Arrigo C, Chiovitti K, Thellung S, Russo C, Di Cola D, Ballerini P, Patrone E, Schettini G, Aceto A, Florio T (2006) Conformation dependent pro-apoptotic activity of the recombinant human prion protein fragment 90-231. Int J Immunopathol Pharmacol 19:339-356
14. Cui Y, Liao XX, Liu W, Guo RX, Wu ZZ, Zhao CM, Chen PX, Feng JQ (2008) A novel role of minocycline: Attenuating morphine antinociceptive tolerance by inhibition of p38 MAPK in the activated spinal microglia. Brain Behav Immun 22:114-123
15. De Luigi A, Colombo L, Diomede L, Capobianco R, Mangieri M, Miccolo C, Limido L, Forloni G, Tagliavini F, Salmona M (2008) The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS ONE 3:e1888
16. Fagan SC, Edwards DJ, Borlongan CV, Xu L, Arora A, Feuerstein G, Hess DC (2004) Optimal delivery of minocycline to the brain: Implication for human studies of acute neuroprotection. Exp Neurol 186:248-251
17. Florio T, Paludi D, Villa V, Principe DR, Corsaro A, Millo E, Damonte G, D'Arrigo C, Russo C, Schettini G, Aceto A (2003) Contribution of two conserved glycine residues to fibrillogenesis of the 106-126 prion protein fragment. Evidence that a soluble variant of the 106-126 peptide is neurotoxic. J Neurochem 85:62-72
18. Forloni G, Iussich S, Awan T, Colombo L, Angeretti N, Girola L, Bertani I, Poli G, Caramelli M, Grazia Bruzzone M, Farina L, Limido L, Rossi G, Giaccone G, Ironside JW, Bugiani O, Salmona M, Tagliavini F (2002) Tetracyclines affect prion infectivity. Proc Natl Acad Sci USA 99:10849-10854
19. Forloni G, Varì M, Colombo L, Bugiani O, Tagliavini F (2003) Prion disease: Time for a therapy? Curr Med Chem-Immun, Endoc Metab Agents 3:185-197
20. Guo G, Bhat NR (2007) p38alpha MAP kinase mediates hypoxia-induced motor neuron cell death: A potential target of minocycline's neuroprotective action. Neurochem Res 32:2160-2166
21. Hetz C, Russelakis-Carneiro M, Maundrell K, Castilla J, Soto C (2003) Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein. EMBO J 22:5435-5445
22. Hughes SR, Khorkova O, Goyal S, Knaeblein J, Heroux J, Riedel NG, Sahasrabudhe S (1998) Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation. Proc Natl Acad Sci USA 95:3275-3280
23. Klein NC, Cunha BA (1995) Tetracyclines. Med Clin North Am 79:789-801
24. Korth C, Peters PJ (2006) Emerging pharmacotherapies for Creutzfeldt-Jakob disease. Arch Neurol 63:497-501
25. Ludewigs H, Zuber C, Vana K, Nikles D, Zerr I, Weiss S (2007) Therapeutic approaches for prion disorders. Expert Rev Anti Infect Ther 5:613-630
26. Marshall CJ (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80:179-185
27. Monnet C, Gavard J, Mege RM, Sobel A (2004) Clustering of cellular prion protein induces ERK1/2 and stathmin phosphorylation in GT1-7 neuronal cells. FEBS Lett 576:114-118
28. Nakajima M, Yamada T, Kusuhara T, Furukawa H, Takahashi M, Yamauchi A, Kataoka Y (2004) Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 17:158-163
29. O'Donovan CN, Tobin D, Cotter TG (2001) Prion protein fragment PrP-(106-126) induces apoptosis via mitochondrial disruption in human neuronal SH-SY5Y cells. J Biol Chem 276:43516-43523
30. Otto M, Cepek L, Ratzka P, Doehlinger S, Boekhoff I, Wiltfang J, Irle E, Pergande G, Ellers-Lenz B, Windl O, Kretzschmar HA, Poser S, Prange H (2004) Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study. Neurology 62:714-718
31. Pahlman S, Hoehner JC, Nanberg E, Hedborg F, Fagerstrom S, Gestblom C, Johansson I, Larsson U, Lavenius E, Ortoft E et al (1995) Differentiation and survival influences of growth factors in human neuroblastoma. Eur J Cancer 31A:453-458
32. Paludi D, Thellung S, Chiovitti K, Corsaro A, Villa V, Russo C, Ianieri A, Bertsch U, Kretzschmar HA, Aceto A, Florio T (2007) Different structural stability and toxicity of PrP(ARR) and PrP(ARQ) sheep prion protein variants. J Neurochem 103:2291-2300
33. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick RJ, Cohen FE et al (1993) Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA 90:10962-10966
34. Pi R, Li W, Lee NT, Chan HH, Pu Y, Chan LN, Sucher NJ, Chang DC, Li M, Han Y (2004) Minocycline prevents glutamate-induced apoptosis of cerebellar granule neurons by differential regulation of p38 and Akt pathways. J Neurochem 91:1219-1230
35. Prusiner SB (2001) Shattuck lecture'neurodegenerative diseases and prions. N Engl J Med 344:1516-1526
36. Riemer C, Burwinkel M, Schwarz A, Gultner S, Mok SW, Heise I, Holtkamp N, Baier M (2008) Evaluation of drugs for treatment of prion infections of the central nervous system. J Gen Virol 89:594-597
37. Ronga L, Langella E, Palladino P, Marasco D, Tizzano B, Saviano M, Pedone C, Improta R, Ruvo M (2007) Does tetracycline bind helix 2 of prion? An integrated spectroscopical and computational study of the interaction between the antibiotic and alpha helix 2 human prion protein fragments. Proteins 66:707-715
38. Simoneau S, Rezaei H, Sales N, Kaiser-Schulz G, Lefebvre-Roque M, Vidal C, Fournier JG, Comte J, Wopfner F, Grosclaude J, Schatzl H, Lasmezas CI (2007) In vitro and in vivo neurotoxicity of prion protein oligomers. PLoS Pathog 3:e125
39. Stirling DP, Koochesfahani KM, Steeves JD, Tetzlaff W (2005) Minocycline as a neuroprotective agent. Neuroscientist 11:308-322
40. Tagliavini F, Forloni G, Colombo L, Rossi G, Girola L, Canciani B, Angeretti N, Giampaolo L, Peressini E, Awan T, De Gioia L, Ragg E, Bugiani O, Salmona M (2000) Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol 300:1309-1322
41. Teng YD, Choi H, Onario RC, Zhu S, Desilets FC, Lan S, Woodard EJ, Snyder EY, Eichler ME, Friedlander RM (2004) Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci USA 101:3071-3076
42. Thellung S, Florio T, Corsaro A, Arena S, Merlino M, Salmona M, Tagliavini F, Bugiani O, Forloni G, Schettini G (2000) Intracellular mechanisms mediating the neuronal death and astrogliosis induced by the prion protein fragment 106-126. Int J Dev Neurosci 18:481-492
43. Thellung S, Villa V, Corsaro A, Arena S, Millo E, Damonte G, Benatti U, Tagliavini F, Florio T, Schettini G (2002) p38 MAP kinase mediates the cell death induced by PrP106-126 in the SH-SY5Y neuroblastoma cells. Neurobiol Dis 9:69-81
44. Thellung S, Villa V, Corsaro A, Pellistri F, Venezia V, Russo C, Aceto A, Robello M, Florio T (2007a) ERK1/2 and p38 MAP kinases control prion protein fragment 90-231-induced astrocyte proliferation and microglia activation. Glia 55:1469-1485
45. Thellung S, Corsaro A, Villa V, Venezia V, Nizzari M, Bisaglia M, Russo C, Schettini G, Aceto A, Florio T (2007b) Amino-terminally truncated prion protein PrP90-231 induces microglial activation in vitro. Ann N Y Acad Sci 1096:258-270
46. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J (2001) Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 21:2580-2588
47. Todd NV, Morrow J, Doh-ura K, Dealler S, O'Hare S, Farling P, Duddy M, Rainov NG (2005) Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease. J Infect 50:394-396
48. Trevitt CR, Collinge J (2006) A systematic review of prion therapeutics in experimental models. Brain 129:2241-2265
49. Uppington KMBD (2007) Modelling neurodegeneration in prion disease - applications for drug development. Expert Opin Drug Discov 2:777-788
50. Uppington KM, Brown DR (2008) Resistance of cell lines to prion toxicity aided by phospho-ERK expression. J Neurochem 105:842-852
51. Valledor AF, Comalada M, Xaus J, Celada A (2000) The differential time-course of extracellular-regulated kinase activity correlates with the macrophage response toward proliferation or activation. J Biol Chem 275:7403-7409
52. Villa V, Corsaro A, Thellung S, Paludi D, Chiovitti K, Venezia V, Nizzari M, Russo C, Schettini G, Aceto A, Florio T (2006) Characterization of the proapoptotic intracellular mechanisms induced by a toxic conformer of the recombinant human prion protein fragment 90-231. Ann N Y Acad Sci 1090:276-291
53. Wang J, Wei Q, Wang CY, Hill WD, Hess DC, Dong Z (2004) Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J Biol Chem 279:19948-19954
54. Weissmann C, Aguzzi A (2005) Approaches to therapy of prion diseases. Annu Rev Med 56:321-344
55. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:1326-1331
56. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM (2004) The promise of minocycline in neurology. Lancet Neurol 3:744-751